The M.S. in Clinical and Translational Therapeutics at UB is a 30-credit hour program, typically completed within 1.5 to 2 years. It offers a unique dual-degree option for PharmD students, allowing them to integrate a year of intensive graduate-level research and coursework into their pharmacy studies. The program emphasizes hands-on research training and clinical experiences, which are crucial for students seeking positions in hospitals, the pharmaceutical industry, and regulatory agencies. Its core mission is to develop a pipeline of clinical and translational research leaders focused on improving patient care through cutting-edge scientific discoveries and therapeutic optimization.
STEM Designated: Yes, the M.S. in Clinical and Translational Therapeutics program at the University at Buffalo is STEM-designated. This designation is highly beneficial for international students on F-1 visas, as it allows them to apply for a 24-month Optional Practical Training (OPT) STEM extension, extending their potential work authorization in the U.S. to a total of 36 months in a field directly related to their degree.
CAATE Accredited: The M.S. in Clinical and Translational Therapeutics program is not accredited by the Commission on Accreditation of Athletic Training Education (CAATE). CAATE is the accrediting body for athletic training programs. The UB program in Clinical and Translational Therapeutics is offered through the School of Pharmacy and Pharmaceutical Sciences and focuses on pharmacy and therapeutic research.
Curriculum: The 30-credit curriculum for the M.S. in Clinical and Translational Therapeutics provides rigorous and individualized training. While core courses typically include "Clinical Research Methods," the program offers five innovative concentrations, allowing students to tailor their learning: "Clinical Trials" (focusing on design and analysis from Phase 1 to 4), "Pharmacotherapy" (understanding pharmacotherapeutics in clinical research, with hospital and outpatient rotations), "Translational Pharmacology" (simulation and in silico modeling), "Experimental Therapeutics" (advancing human pharmacology in the lab), and "Pharmaceutical Outcomes" (health services research, pharmacoepidemiology, and outcomes research). These tracks combine didactic coursework with experiential rotations and a pragmatic focus on research.
Research Focus: The M.S. in Clinical and Translational Therapeutics at UB has a profound research focus, aiming to bridge scientific discoveries with the treatment of disease. The program is deeply integrated with the research activities of UB's School of Pharmacy and Pharmaceutical Sciences and likely leverages the resources of the Buffalo Clinical and Translational Research Center. Faculty mentors, who are internationally renowned, guide students in cutting-edge scientific discoveries focused on therapeutic individualization and optimization. Research areas span clinical trial design, pharmacotherapeutic research impacting patient care, translational in silico modeling, advancing human pharmacology in the laboratory, and pharmaceutical outcomes research. The program emphasizes hands-on research training, preparing students to contribute to the pipeline of future clinical and translational research leaders.
Industry Engagement: The M.S. in Clinical and Translational Therapeutics program at UB actively prepares graduates for engagement with the pharmaceutical industry and regulatory agencies, as well as clinical positions in hospitals. The hands-on research training and clinical experiences offered through the program are specifically designed to meet the needs of these sectors. The curriculum's focus on clinical trials, pharmacotherapy, and pharmaceutical outcomes directly aligns with industry demands. Graduates are well-positioned for employment in various roles within pharmaceutical companies, contract research organizations (CROs), and regulatory bodies such as the FDA, where their expertise in advancing therapeutics and optimizing patient care is highly valued.
Global Perspective: The M.S. in Clinical and Translational Therapeutics at UB inherently fosters a global perspective, as the challenges of disease combat and therapeutic optimization are universal. The program aims to develop future clinical and translational research leaders, whose discoveries and insights can impact patient care globally. The research conducted, particularly in areas like clinical trials and translational pharmacology, often draws on international methodologies and can have worldwide implications. While specific international partnerships may vary, the broader context of pharmaceutical development and global health necessitates an understanding of diverse patient populations and regulatory landscapes. The university's diverse faculty and student body also contribute to a global learning environment, enriching discussions with varied international perspectives.